Bildkälla: Stockfoto

Xbrane Biopharma: Simply Phenomenal News - Redeye

Redeye gives its view following the announcement of positive interim data from the phase III study for Xlucane. The outcome in Xplore provides considerable validation of Xbrane's in-house capabilities and pipeline.

Redeye gives its view following the announcement of positive interim data from the phase III study for Xlucane. The outcome in Xplore provides considerable validation of Xbrane's in-house capabilities and pipeline.
Börsvärldens nyhetsbrev
ANNONSER